---
title: "Ord Minnett Sticks to Its Buy Rating for Qoria (FMZNF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284293059.md"
description: "Ord Minnett analyst Milo Ferris has reaffirmed a Buy rating for Qoria (FMZNF), setting a price target of A$0.56. Ferris, who specializes in the Technology sector, has an average return of -12.8% and a 38.46% success rate on his stock recommendations. Additionally, Bell Potter also maintains a Buy rating for Qoria with a price target of A$0.50, as reported on April 26."
datetime: "2026-04-28T01:38:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284293059.md)
  - [en](https://longbridge.com/en/news/284293059.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284293059.md)
---

# Ord Minnett Sticks to Its Buy Rating for Qoria (FMZNF)

In a report released today, Milo Ferris from Ord Minnett maintained a Buy rating on Qoria, with a price target of A$0.56.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Ferris covers the Technology sector, focusing on stocks such as Qoria, Technology One Limited, and DUG Technology Ltd. According to TipRanks, Ferris has an average return of \-12.8% and a 38.46% success rate on recommended stocks.

In a report released on April 26, Bell Potter also maintained a Buy rating on the stock with a A$0.50 price target.

### Related Stocks

- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [IXJ.AU](https://longbridge.com/en/quote/IXJ.AU.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [TNE.AU](https://longbridge.com/en/quote/TNE.AU.md)
- [DUG.AU](https://longbridge.com/en/quote/DUG.AU.md)

## Related News & Research

- [05:22 ETEnergenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026](https://longbridge.com/en/news/284533464.md)
- [ZAWYA: Emirates Drug Establishment approves first nasal epinephrine spray as alternative to injections for severe allergic reaction](https://longbridge.com/en/news/284603051.md)
- [Sapio Sciences brings Claude Cowork to the lab](https://longbridge.com/en/news/284585524.md)
- [Summit's Q1 Net Loss Widens; Expects Patient Enrollment In Phase III ILLUMINE Study In Q2,2026](https://longbridge.com/en/news/284871928.md)
- [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md)